Storming the Castle with TCP.

Abstract

In this issue of Blood, Zhang et al report on the treatment of newly diagnosed idiopathic multicentric Castleman disease (iMCD) with the combination of oral thalidomide, cyclophosphamide, and prednisone (TCP), providing an alternative to anti–interleukin-6 (IL-6) monoclonal antibodies (mAbs), especially when these are not readily available.1